Last reviewed · How we verify
Reduning injection
Reduning injection, developed by the China Academy of Chinese Medical Sciences, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent until 2028. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Reduning injection |
|---|---|
| Also known as | Oseltamivir phosphate granule simulants |
| Sponsor | China Academy of Chinese Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever (NA)
- Clinical Study of Reduning Injection for the Treatment of Influenza in Children (PHASE4)
- A Registry Study of 100 Thousand Cases of Pediatric Patients on Reduning Injection（a Chinese Medicine Injection）Used in Hospitals in China
- A Registry Study on Reduning（a Chinese Medicine Injection）Used in Hospitals in China
- A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease (NA)
- A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reduning injection CI brief — competitive landscape report
- Reduning injection updates RSS · CI watch RSS
- China Academy of Chinese Medical Sciences portfolio CI